BACKGROUND: Patients with recurrent ovarian cancer have limited options, especially in the context of relapse less than six months from primary platinum-based therapy. This Gynecologic Oncology Group (GOG) study was conducted to evaluate the impact of the histone deacetylase inhibitor, belinostat, in combination with carboplatin in women with platinum-resistant ovarian cancer. METHODS: Eligible patients had measurable, recurrent disease within six months of their last dose of a platinum-based combination. Belinostat was dosed at 1000 mg/m(2) daily for five days with carboplatin AUC 5 on day three of 21-day cycles. The primary endpoint was overall response rate (ORR), using a two-stage design. RESULTS: Twenty-nine women enrolled on study and 27 were evaluable. The median number of cycles given was two (range 1-10). One patient had a complete response and one had a partial response, for an ORR of 7.4% (95% CI, .9%-24.3%). Twelve patients had stable disease while eight had increasing disease. Response could not be assessed in five (18.5%). Grade 3 and 4 events occurring in more than 10% of treated patients were uncommon and limited to neutropenia (22.2%), thrombocytopenia (14.8%), and vomiting (11.1%). The median progression-free survival (PFS) was 3.3 months and overall survival was 13.7 months. PFS of at least six months was noted in 29.6% of patients. Due to the lack of drug activity, the study was closed after the first-stage. CONCLUSIONS: The addition of belinostat to carboplatin had little activity in a population with platinum-resistant ovarian cancer.
BACKGROUND:Patients with recurrent ovarian cancer have limited options, especially in the context of relapse less than six months from primary platinum-based therapy. This Gynecologic Oncology Group (GOG) study was conducted to evaluate the impact of the histone deacetylase inhibitor, belinostat, in combination with carboplatin in women with platinum-resistant ovarian cancer. METHODS: Eligible patients had measurable, recurrent disease within six months of their last dose of a platinum-based combination. Belinostat was dosed at 1000 mg/m(2) daily for five days with carboplatin AUC 5 on day three of 21-day cycles. The primary endpoint was overall response rate (ORR), using a two-stage design. RESULTS: Twenty-nine women enrolled on study and 27 were evaluable. The median number of cycles given was two (range 1-10). One patient had a complete response and one had a partial response, for an ORR of 7.4% (95% CI, .9%-24.3%). Twelve patients had stable disease while eight had increasing disease. Response could not be assessed in five (18.5%). Grade 3 and 4 events occurring in more than 10% of treated patients were uncommon and limited to neutropenia (22.2%), thrombocytopenia (14.8%), and vomiting (11.1%). The median progression-free survival (PFS) was 3.3 months and overall survival was 13.7 months. PFS of at least six months was noted in 29.6% of patients. Due to the lack of drug activity, the study was closed after the first-stage. CONCLUSIONS: The addition of belinostat to carboplatin had little activity in a population with platinum-resistant ovarian cancer.
Authors: Denise A Yardley; Roohi R Ismail-Khan; Bohuslav Melichar; Mikhail Lichinitser; Pamela N Munster; Pamela M Klein; Scott Cruickshank; Kathy D Miller; Min J Lee; Jane B Trepel Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Cheryl A Brewer; John A Blessing; Robert A Nagourney; Mark Morgan; Parviz Hanjani Journal: Gynecol Oncol Date: 2006-04-27 Impact factor: 5.482
Authors: Suresh S Ramalingam; Chandra P Belani; Christopher Ruel; Paul Frankel; Barbara Gitlitz; Marianna Koczywas; Igor Espinoza-Delgado; David Gandara Journal: J Thorac Oncol Date: 2009-01 Impact factor: 15.609
Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé Journal: Lancet Date: 2003-06-21 Impact factor: 79.321
Authors: Haller J Smith; Tyler R McCaw; Angelina I Londono; Ashwini A Katre; Selene Meza-Perez; Eddy S Yang; Andres Forero; Donald J Buchsbaum; Troy D Randall; J Michael Straughn; Lyse A Norian; Rebecca C Arend Journal: Cancer Date: 2018-11-13 Impact factor: 6.860
Authors: Thehang Luu; Paul Frankel; Jan H Beumer; Dean Lim; Mihaela Cristea; Leonard J Appleman; Heinz J Lenz; David R Gandara; Brian F Kiesel; Richard L Piekarz; Edward M Newman Journal: Cancer Chemother Pharmacol Date: 2019-09-14 Impact factor: 3.333
Authors: Robert Brown; Edward Curry; Luca Magnani; Charlotte S Wilhelm-Benartzi; Jane Borley Journal: Nat Rev Cancer Date: 2014-09-25 Impact factor: 60.716
Authors: Javier Martinez-Useros; Mario Martin-Galan; Maria Florez-Cespedes; Jesus Garcia-Foncillas Journal: Cancers (Basel) Date: 2021-06-27 Impact factor: 6.639